Publication | Closed Access

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Tildrakizumab Versus PlaceboResurface 1Clinical TrialsPsoriatic ArthritisClinical DermatologyChronic Plaque PsoriasisPharmacotherapyDermatologyMedicine